Ji-Eun Seo

Ji-Eun Seo

Auto-generated profile, based on publicly available information

Ji-Eun Seo

Division of Genetic and Molecular Toxicology, National Center for Toxicological Research, U.S. Food and Drug Administration

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 July 2025 in Regulatory Toxicology and Pharmacology
Verified
Journal Article
Closed access
JSJi-Eun Seo
Ji-Eun Seo
HXHannah Xu
Hannah Xu
XLXilin Li
Xilin Li
AAAisar H. Atrakchi
Aisar H. Atrakchi
TMTimothy McGovern
Timothy McGovern
XGXiaoqing Guo
Xiaoqing Guo

12 June 2025 in Journal of Environmental Science and Health, Part C
Verified
Journal Article
Closed access
YLYuan Le
Yuan Le
XLXilin Li
Xilin Li
XGXiaoqing Guo
Xiaoqing Guo
JSJi-Eun Seo
Ji-Eun Seo
MMMugimane G. Manjanatha
Mugimane G. Manjanatha
NMNan Mei
Nan Mei
Black cohosh (Actaea racemosa L) has been utilized for centuries by Native Americans as a traditional herbal medicine. The rhizome and root extract from black cohosh (BCE) is one of the most popular herbal dietary supplements worldwide. Due to its claimed estrogen-like effects, contemporary uses of black cohosh products are primarily for alleviating menopausal and perimenopausal symptoms. However, recent studies indicate that BCE is not only ineffective for menopausal therapy, but also induces genotoxicity through an aneugenic mode of action (MoA). Adverse effects induced by BCE have been reported in humans, with many case studies documenting outcomes ranging from mild reactions to acute liver damage and even death. Consequently, concerns about the safety of BCE have emerged. There are more than 100 chemical constituents in black cohosh products, including triterpene glycosides (>40 chemicals), polyphenols (>20 chemicals), and nitrogenous compounds (>70 chemicals). Therefore, commercially available BCE products can differ markedly in composition, leading to the potential for variable bioactivities among these complex commercial products. This review presents the latest information on the toxicological effects of BCE from both in vivo and in vitro experiments and summarizes the adverse effects of BCE in human clinical trials.

22 August 2025 in Journal of Environmental Science and Health, Part C
Verified
Journal Article
Closed access
XGXiaoqing Guo
Xiaoqing Guo
JSJi-Eun Seo
Ji-Eun Seo
JMJaime Miranda-Colon
Jaime Miranda-Colon
HXHannah Xu
Hannah Xu
JRJavier Revollo
Javier Revollo
RHRobert H. Heflich
Robert H. Heflich
Accurately evaluating chemical risk may benefit from the development of human-relevant models capable of capturing the effects of treatments that closely mimic real-world environmental and pharmaceutical exposures. Building on our previous work (Seo et al. Arch Toxicol 98:1919-1935),1 where cytotoxicity compromised mutation detection following short-term treatments, this study investigated mutation accumulation in both 2D and 3D HepaRG cultures following 7- and 14-day exposures with relatively non-cytotoxic N-nitrosodimethylamine (NDMA) concentrations. A multi-endpoint approach was employed to assess NDMA-induced DNA damage, micronucleus formation, and mutagenesis. Seven-day NDMA treatments were not cytotoxic but produced concentration-dependent increases in DNA damage and mutations. After 14 days of exposure, the highest NDMA concentrations produced no more than 30% cytotoxicity, and induced greater mutation frequencies compared to the 7-day exposures. Overall, the mutation frequencies induced by NDMA exhibited concentration- and treatment-duration-dependent relationships in both 2D and 3D HepaRG cultures, with notably higher mutation frequencies in 3D spheroids than in 2D cultures. Quantitative analysis by benchmark concentration (BMC) modeling demonstrated lower BMC values in 3D spheroids compared to their 2D counterparts. The predominant mutation in NDMA-treated cultures was T→C transition. These findings indicate the value of extended exposure periods for conducting in vitro genotoxicity testing in HepaRG cells.